Ezra Announces FDA Acceptance of Filing of New Drug Application For EZR-104 for the Treatment of Hypertension and Heart Failure
Little Rock, January 18, 2017 -- Ezra Innovations, LLC (Ezra) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for an investigational drug product, EZR-104, for the treatment of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Cardiology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart | Heart Failure | Hypertension | New Drug Applications